View Presentation Slides - PCSS-O

More documents

Recommendations

Info

Participant Opioid of Choice (OOC) 16 (11%) 1 (0.6%) 9 (6.3%) codeine heroin fentanyl 23 (16%) methadone hydrocodone 18 (12.5%) hydromorphone oxycodone 1 (0.6%) 63 (44%) methadone hydromorphone heroin codeine hydrocodone oxycodone fentanyl
Months Average duration of opioid use 300 255 250 By opioid of choice 200 150 100 121 95 90 84 84 50 0 Opioid of choice Average: 115 Months Range: 7-360 Months
Page 1 and 2: Patricia Pade, MD University of Col
Page 3 and 4: Objectives • To provide a brief o
Page 5 and 6: Chronic Pain • 116 million people
Page 7 and 8: Opioid Use • Use of opioids has i
Page 9 and 10: Fatal Drug Poisoning • Between 19
Page 11 and 12: Opioid Pharmacology: How do these M
Page 13 and 14: • Tolerance: Repeated Dosing: Opi
Page 15 and 16: Brief pharmacology overview: full o
Page 17 and 18: Brief pharmacology overview: opioid
Page 19 and 20: The Use of Buprenorphine/Naloxone t
Page 21 and 22: The Problem for Veterans
Page 23 and 24: Improvement Change: Creation of Co-
Page 25 and 26: Patient population • Referrals fr
Page 27 and 28: Initial Evaluation A. PAIN Detailed
Page 29 and 30: Buprenorphine induction process •
Page 31: Study participants Participant Data
Page 35 and 36: Number Number Number 60 40 Co-morbi
Page 37 and 38: Adjuvant Medications Na and Interve
Page 39 and 40: Ongoing monitoring for compliance
Page 41 and 42: 93/143 patients remained in treatme
Page 43 and 44: Conclusions 11. Patients with co-oc
Page 45 and 46: Office Based Opioid Treatment: Bupr
Page 47: References 1. Institute of Medicine

View Presentation Slides - PCSS-O

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?